CN111411075A - 一种构建人心肌细胞凋亡模型的方法 - Google Patents
一种构建人心肌细胞凋亡模型的方法 Download PDFInfo
- Publication number
- CN111411075A CN111411075A CN202010160710.6A CN202010160710A CN111411075A CN 111411075 A CN111411075 A CN 111411075A CN 202010160710 A CN202010160710 A CN 202010160710A CN 111411075 A CN111411075 A CN 111411075A
- Authority
- CN
- China
- Prior art keywords
- angiotensin
- hipsc
- apoptosis
- days
- ang
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000006907 apoptotic process Effects 0.000 title claims abstract description 39
- 238000000034 method Methods 0.000 title claims abstract description 20
- 230000002107 myocardial effect Effects 0.000 title claims abstract description 15
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 claims abstract description 47
- 101800000733 Angiotensin-2 Proteins 0.000 claims abstract description 46
- 102000005862 Angiotensin II Human genes 0.000 claims abstract description 44
- 229950006323 angiotensin ii Drugs 0.000 claims abstract description 44
- 210000004413 cardiac myocyte Anatomy 0.000 claims description 13
- 238000012258 culturing Methods 0.000 claims description 3
- 230000001640 apoptogenic effect Effects 0.000 claims description 2
- 230000031592 cardiac muscle cell apoptotic process Effects 0.000 claims description 2
- 239000000411 inducer Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 238000002474 experimental method Methods 0.000 abstract description 4
- 230000001939 inductive effect Effects 0.000 abstract description 3
- 230000000144 pharmacologic effect Effects 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- 238000011282 treatment Methods 0.000 description 15
- 230000014509 gene expression Effects 0.000 description 11
- 239000002609 medium Substances 0.000 description 10
- 206010019280 Heart failures Diseases 0.000 description 9
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 102000004121 Annexin A5 Human genes 0.000 description 5
- 108090000672 Annexin A5 Proteins 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 230000030833 cell death Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 3
- RVNZEJNWTUDQSC-JOCHJYFZSA-N (2r)-n-(6-aminohexyl)-1-tridecanoylpyrrolidine-2-carboxamide Chemical compound CCCCCCCCCCCCC(=O)N1CCC[C@@H]1C(=O)NCCCCCCN RVNZEJNWTUDQSC-JOCHJYFZSA-N 0.000 description 3
- 102000008873 Angiotensin II receptor Human genes 0.000 description 3
- 108050000824 Angiotensin II receptor Proteins 0.000 description 3
- 102100027308 Apoptosis regulator BAX Human genes 0.000 description 3
- 108050006685 Apoptosis regulator BAX Proteins 0.000 description 3
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 3
- 101000945496 Homo sapiens Proliferation marker protein Ki-67 Proteins 0.000 description 3
- 206010020880 Hypertrophy Diseases 0.000 description 3
- 102100034836 Proliferation marker protein Ki-67 Human genes 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 102400000345 Angiotensin-2 Human genes 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102100031150 Growth arrest and DNA damage-inducible protein GADD45 alpha Human genes 0.000 description 2
- 101001066158 Homo sapiens Growth arrest and DNA damage-inducible protein GADD45 alpha Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 2
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 1
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 1
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical compound CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- 101100107522 Mus musculus Slc1a5 gene Proteins 0.000 description 1
- WRKPZSMRWPJJDH-UHFFFAOYSA-N N-(6-methyl-1,3-benzothiazol-2-yl)-2-[(4-oxo-3-phenyl-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)thio]acetamide Chemical compound S1C2=CC(C)=CC=C2N=C1NC(=O)CSC1=NC=2CCSC=2C(=O)N1C1=CC=CC=C1 WRKPZSMRWPJJDH-UHFFFAOYSA-N 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- 108090000028 Neprilysin Proteins 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 102100040372 Type-2 angiotensin II receptor Human genes 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002170 aldosterone antagonist Substances 0.000 description 1
- 229940083712 aldosterone antagonist Drugs 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- -1 proliferation Chemical compound 0.000 description 1
- 108091006082 receptor inhibitors Proteins 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 208000004124 rheumatic heart disease Diseases 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000012128 staining reagent Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0657—Cardiomyocytes; Heart cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/32—Angiotensins [AT], angiotensinogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明公开了一种构建人心肌细胞凋亡模型的方法。发明人在研究过程中意外发现,一定浓度之上的血管紧张素Ⅱ处理hiPSC‑CM一定时间后,可以有效诱导hiPSC‑CM凋亡。本发明一些实例,使用血管紧张素Ⅱ诱导人心肌细胞的凋亡,构建与人体更加接近的心肌细胞凋亡模型,为后续的药理实验提供有力的工具和方法。
Description
技术领域
本发明涉及一种细胞模型的构建方法,特别涉及一种构建人心肌细胞凋亡模型的方法。
背景技术
心力衰竭是在老年人中非常流行的慢性病,且它的患病率和发病率正逐年上涨。全球接近2600万人次正在遭受心力衰竭的痛苦,5年内的存活率少于53%。每年全球因慢性心力衰竭治疗而造成的经济负担超过1080亿美元。心力衰竭是很多心血管疾病的末期表现,例如,缺血性心脏病,风湿性心脏病。由于个体差异,使得心力衰竭的治疗难以达到满意的效果。十分迫切建立评估不同药物对每个心力衰竭病人的效果的方法。
随着iPS(诱导多能干细胞)技术的发展、心肌细胞分化及纯化方法的建立,使得我们可以在体外制备来自患者的心肌细胞。这些心肌细胞已经协助我们研究心血管疾病,(如:长QT间期综合征,心律不齐,肥厚型心肌病,扩张型心肌病,线粒体心肌病,等)以及进行治疗心血管疾病药物的药理实验和心脏毒性试验(如:醛固酮拮抗剂,血管紧张素转化酶抑制剂,血管紧张素II受体阻断剂,β受体阻滞剂,血管紧张素脑啡肽酶受体抑制剂,等)。
建立人心肌细胞凋亡模型的方法对后续的研究十分重要,现有技术一般使用双氧水(过氧化氢)诱导细胞的凋亡。而过氧化氢并不是正常情况下导致人心力衰竭的原因,应用范围及其有限。
作为RAS系统(肾素-血管紧张素系统,能调节心血管疾病的病理过程,例如心力衰竭和高血压)的主要效应因子,血管紧张素II(Angiotensin II)通过激活血管紧张素II受体引起细胞凋亡,细胞肥大和心肌重构。因此,由血管紧张素II诱导的心肌细胞凋亡更加贴合和反映真实情况下的心力衰竭,在心力衰竭的病例机制中扮演着决定性角色。有研究显示,血管紧张素II可诱导hiPSC(人诱导多能干细胞)和hESC(人胚胎干细胞)来源的心肌细胞肥大,也有报道显示血管紧张素II的处理组和未处理组的细胞死亡和存活率无显著性差异。然而,没有研究表明血管紧张素II可以引起hiPSC-CM(人诱导多能干细胞分化的心肌细胞)凋亡。血管紧张素II受体有两种类型:AT1和AT2。一般认为,AT1参与血管紧张素II的主要作用,如增殖、肥大和纤维化,而血管紧张素II通过与AT2结合而引起细胞凋亡和心脏重构。对hiPSC-CM的基因表达分析,显示hiPSC-CM的AT2表达缺失,这可能是导致以前报道的血管紧张素II未能引起hiPSC-CM细胞凋亡的原因。
构建一种能更为有效反应真实心血管的hiPSC-CM细胞凋亡模型,具有非常重要的意义。
发明内容
本发明的目的在于克服现有技术的不足,提供一种构建可以更为有效反应真实心血管的hiPSC-CM细胞凋亡模型的方法。
本发明所采取的技术方案是:
本发明的第一个方面,提供:
血管紧张素Ⅱ在制备hiPSC分化而来的心肌细胞凋亡诱导剂中的应用。
在一些实例中,血管紧张素Ⅱ的使用终浓度为100μM~1mM。
在一些实例中,血管紧张素Ⅱ的使用终浓度为150μM~1mM。
在一些实例中,血管紧张素Ⅱ的诱导时间不少于6天。
在一些实例中,血管紧张素Ⅱ的诱导时间为6~10天。
血管紧张素Ⅱ的使用终浓度大于100μM时,诱导培养超过6天即可有效诱导hiPSC-CM凋亡。
本发明的第二个方面,提供:
血管紧张素Ⅱ在构建hiPSC分化而来的心肌细胞凋亡模型中的应用。
在一些实例中,血管紧张素Ⅱ的使用终浓度为100μM~1mM。
在一些实例中,血管紧张素Ⅱ的使用终浓度为150μM~1mM。
在一些实例中,血管紧张素Ⅱ的诱导时间不少于6天。
在一些实例中,血管紧张素Ⅱ的诱导时间为6~10天。
本发明的第三个方面,提供:
一种构建hiPSC分化而来的心肌细胞凋亡模型的方法,包括在hiPSC分化而来的心肌细胞的培养液中添加终浓度为100μM~1mM的血管紧张素Ⅱ,继续培养得到获得凋亡的hiPSC-CM。
在一些实例中,所述培养液中hiPSC-CM的浓度为(2~10)×104/mL。
在一些实例中,所述继续培养的时间不少于6天。
在一些实例中,所述继续培养的时间为6~10天。
在一些实例中,所述培养液中血管紧张素Ⅱ的终浓度为150μM~1mM。
实验结果表明,更高浓度(1mM)的血管紧张素Ⅱ诱导,细胞凋亡的比例更高。可以根据需要调节血管紧张素Ⅱ的使用浓度。
本发明的有益效果是:
发明人在研究过程中意外发现,一定浓度之上的血管紧张素Ⅱ处理hiPSC-CM一定时间后,可以有效诱导hiPSC-CM凋亡。
本发明一些实例,使用血管紧张素Ⅱ诱导人心肌细胞的凋亡,构建与人体更加接近的心肌细胞凋亡模型,为后续的药理实验提供有力的工具和方法。
附图说明
图1是不同浓度AngⅡ短期处理对hiPSC-CM活力的影响;
图2是不同浓度AngⅡ长期处理对hiPSC-CM活力的影响;
图3是不同浓度AngⅡ处理2天对hiPSC-CM各基因表达的影响;
图4是不同浓度AngⅡ处理10天对hiPSC-CM各基因表达的影响;
图5是不同浓度AngⅡ处理10天的流式细胞分析结果。
具体实施方式
下面结合实验,进一步说明本发明的技术方案。
1、按常规的,公认的方法获得iPS细胞。
2、按常规的,公认的方法将iPS细胞分化成心肌细胞并进行纯化。
或具体的,可参照如下方法获得纯化的hiPSC-CM。
hiPSC-CM的获得
1.1hiPSC细胞的培养:将人诱导多能干细胞DYR0100(ATCC)接种于Matrigel基质(康宁,354277)包被的平板上,然后用Stemflex培养基(Gibco,A3349401)进行培养。StemFlex培养基每两天更换一次。iPSC每隔3天传代一次,或在细胞培养达到80-90%汇合度时传代。传代过程中用1×DPBS(Gibco,14040133)冲洗1次,然后在室温下用使用1×DPBS(Gibco,14190144)稀释的0.5mM EDTA(Invitgen,15575020)在中处理10min。传代比为1:3-1:6。
1.2hiPSC细胞的分化:在RPMI-BSA培养基[RPMI1640培养基(HyClone,SH30027.01)+213μg/mL AA2P(l-抗坏血酸2-磷酸镁)(A8960,Sigma)和0.1%牛血清白蛋白(A1470,Sigma)]中,加入CHIR99021(Tcriis4423,终浓度为10mmol M)处理iPSC 24小时,然后换RPMI-BSA培养基静止培养。在分化第4天,在RPMI-BSA培养基中加入IWP2(Tcriis3533,终浓度5μM)处理细胞。48h后换用RPMI-BSA培养基。在随后的实验中,用RPMI1640培养基加3%的血清替代物(Gibco,10828-028)培养心肌细胞。
1.3hiPSC-CM细胞的纯化:使用代谢选择方法纯化hiPSC-CM。代谢选择培养基为添加0.1%牛血清白蛋白(SIGMA,A1470)和1×亚油酸-油酸-白蛋白(SIGMA,L9655)的DMEM培养基(无葡萄糖)(Gibco,11966-025)。用代谢选择培养基处理细胞3~6d。培养基每2天更换一次。心肌细胞纯度可高达99%。
血管紧张素Ⅱ诱导hiPSC-CM凋亡
2.1血管紧张素Ⅱ诱导hiPSC-CM细胞凋亡:
纯化后用添加不同量(1nM,10nM,100nM,1μM,10μM,100μM,1mM)血管紧张素Ⅱ的心肌细胞培养液(MedChemExpress,HY-13948)进行血管紧张素Ⅱ处理,每隔2天更换一次血管紧张素Ⅱ培养液。
2.2hiPSC-CM凋亡验证:
2.2.1不同浓度和不同培养时间AngⅡ处理对hiPSC-CM的活性影响
按说明书用PrestoBlue细胞活性检测试剂(Invitgen,A13261)检测心肌细胞活性,结果如图1和图2所示。
2.2.2AngⅡ对hiPSC-CM细胞凋亡和增殖相关基因表达水平的影响
用UNLQ-10柱Trizol总RNA分离试剂盒(Sangon Biotech,B511321-0100)提取总RNA,然后用DNase I(Sangon Biotech,B618252)处理30min。mRNA使用iScript ReverseTranscription Supermix(Bio-Rad,1708841)进行逆转录。使用PikoReal-time PCRsystem(Thermo Fisher)和Sso AdvancedTMUniversalGreen SuperMix(BioRad,1725271)进行定量聚合酶链反应。定量PCR的引物来自先前报告,具体如下(从5‘到3’):
结果如图3和图4所示。
2.2.3长时间(6d和10d)高浓度(100μM和1mM)AngⅡ处理诱导hiPSC-CM细胞凋亡
从细胞活性检测结果看,仅长期AngⅡ处理使hiPSC-CM得活性下降。
因此,为了研究细胞凋亡率,我们对AngⅡ处理10天的hiPSC-CM细胞进行凋亡分析。
应用凋亡检测试剂盒Annexin V,Alexa FluorTM488conjugate(InvitgenV13201)检测AngⅡ处理和未处理心肌细胞的凋亡情况。心肌细胞用凋亡标记物Annexin V标记后,用FACSAriaTMII流式细胞分析仪(BD)进行分析。结果如图5所示,图中,经0nM(未处理)、100μM和1mM AngⅡ处理10天的hiPSC-CM用凋亡标记物Annexin V标记,使用流式细胞分析仪进行分析。未染色组用DPBS缓冲液代替Annexin V染色试剂。
实验结果:
通过测试hiPSC-CM在不同浓度和培养时间,包括8个浓度(0nM(未经处理)、1nM、10nM、100nM、1μM、10μM、100μM an和1mM))和4个处理时间(24小时、48小时、6天和10天)确定血管紧张素Ⅱ的促凋亡作用。在AngⅡ短期处理(24小时和48小时),无论浓度高低,对照组hiPSC-CM和AngⅡ处理组hiPSC-CM在细胞活性上,均无显著差异(图1)。相反的,经过6天处理AngⅡ100μM组和1mM组的hiPSC-CM细胞活性显著降低(细胞活力差异倍数,100μM对比未处理对照组为0.763;1mM比未处理对照组为0.762。p<0.001极显著差异)。经过10天处理,10μM AngⅡ甚至导致细胞活性急下降20%(细胞活力差异倍数,10μM对比未处理对照组为0.795;100μM对比未处理对照组为0.638;1mM对比未处理对照组为0.590.10μM组p<0.05有统计学差异;100μM和1mM组,p<0.001极显著差异)。其他浓度AngⅡ细胞活性似乎略有下降但无统计学意义(图2)。
在血管紧张素Ⅱ处理2天的hiPSC-CM中,1nM和1μM血管紧张素Ⅱ没有改变BCL2、TP53和GADD45A的表达水平,而1mM(1mM)血管紧张素Ⅱ使BAX表达增加1.2 5倍,BCL2表达下调。3种浓度的AngⅡ处理后,MKI67的表达均降低。1mM AngⅡ作用10天后,BAX、TP53、GADD45A和MKI67的表达明显上调(分别为2.25、1.81、1.83和2.53倍),而BLD2的表达下降了70%。与2天处理相反,10天处理使MKI67在所有三个浓度下的表达均升高。BAX编码促凋亡蛋白,在凋亡途径中起凋亡激活剂的作用。相反,BCL2是一种抗凋亡分子,可以促进细胞存活,阻止细胞程序性死亡。TP53和GADD45A是细胞周期调控基因,也被报道介导细胞凋亡。MKI67和PCNA是细胞增殖的标志。值得注意的是,1mM AngⅡ在短期内已引起BAX表达上调,BCL2表达下调,且随着孵育时间的延长,作为细胞凋亡指标的BAX/BCL2比值急剧升高。此外,1mM AngⅡ还可增加TP53和GADD45A的表达,表明心肌细胞处于凋亡状态。
收集10天处理的hiPSC-CM,用结合了绿色荧光基团Alexa Fluor 488的Annexin V染料染色,然后用流式细胞术分析。如图5所示,未处理的hiPSC-CM组平均凋亡率为4.1%,而100μM和1mM AngⅡ处理组hiPSC-CM平均细胞凋亡率分别为12.7%和15.6%(图5)。这表明100μM AngⅡ处理组的细胞凋亡率为未处理组的3.08倍,1mM AngⅡ处理组的凋亡率为未处理组的3.74倍。
SEQUENCE LISTING
<110> 广东源心再生医学有限公司
<120> 一种构建人心肌细胞凋亡模型的方法
<130> Ang Ⅱ
<160> 14
<170> PatentIn version 3.5
<210> 1
<211> 20
<212> DNA
<213> 人工序列
<400> 1
caaactggtg ctcaaggccc 20
<210> 2
<211> 20
<212> DNA
<213> 人工序列
<400> 2
gggcgtccca aagtaggaga 20
<210> 3
<211> 20
<212> DNA
<213> 人工序列
<400> 3
ctggtggaca acatcgccct 20
<210> 4
<211> 24
<212> DNA
<213> 人工序列
<400> 4
tcttcagaga cagccaggag aaat 24
<210> 5
<211> 20
<212> DNA
<213> 人工序列
<400> 5
tgtgcctgct cgaccctaca 20
<210> 6
<211> 24
<212> DNA
<213> 人工序列
<400> 6
tgaaatagcg atgtgacatg tgct 24
<210> 7
<211> 19
<212> DNA
<213> 人工序列
<400> 7
tttggtgcag ctcaccctg 19
<210> 8
<211> 20
<212> DNA
<213> 人工序列
<400> 8
cgcgttatct tcggccctta 20
<210> 9
<211> 20
<212> DNA
<213> 人工序列
<400> 9
gcgtgtttgt gcctgtcctg 20
<210> 10
<211> 20
<212> DNA
<213> 人工序列
<400> 10
tggtttcttc tttggctggg 20
<210> 11
<211> 20
<212> DNA
<213> 人工序列
<400> 11
gatgccctgg aggaagtgct 20
<210> 12
<211> 21
<212> DNA
<213> 人工序列
<400> 12
gagccacatc tctgtcgtcg t 21
<210> 13
<211> 20
<212> DNA
<213> 人工序列
<400> 13
tgggtgtgaa ccatgagaag 20
<210> 14
<211> 20
<212> DNA
<213> 人工序列
<400> 14
gtgtcgctgt tgaagtcaga 20
Claims (10)
1.血管紧张素Ⅱ在制备hiPSC分化而来的心肌细胞凋亡诱导剂中的应用。
2.根据权利要求1所述的应用,其特征在于:血管紧张素Ⅱ的使用终浓度为100μM~1mM。
3.血管紧张素Ⅱ在构建hiPSC分化而来的心肌细胞凋亡模型中的应用。
4.根据权利要求3所述的应用,其特征在于:血管紧张素Ⅱ的使用终浓度为100μM~1mM。
5.根据权利要求1~4任一项所述的应用,其特征在于:血管紧张素Ⅱ持续处理hiPSC分化而来的心肌细胞的时间不少于6天。
6.一种构建hiPSC分化而来的心肌细胞凋亡模型的方法,包括在hiPSC分化而来的心肌细胞的培养液中添加终浓度为100μM~1mM的血管紧张素Ⅱ,继续培养得到获得凋亡的hiPSC-CM。
7.根据权利要求6所述的方法,其特征在于:所述培养液中hiPSC-CM的浓度为(2~10)×104/mL。
8.根据权利要求6或7所述的方法,其特征在于:所述继续培养的时间不少于6天。
9.根据权利要求8所述的方法,其特征在于:所述继续培养的时间为6~10天。
10.根据权利要求6或7所述的方法,其特征在于:所述培养液中血管紧张素Ⅱ的终浓度为150μM~1mM。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010160710.6A CN111411075A (zh) | 2020-03-10 | 2020-03-10 | 一种构建人心肌细胞凋亡模型的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010160710.6A CN111411075A (zh) | 2020-03-10 | 2020-03-10 | 一种构建人心肌细胞凋亡模型的方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111411075A true CN111411075A (zh) | 2020-07-14 |
Family
ID=71491000
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010160710.6A Pending CN111411075A (zh) | 2020-03-10 | 2020-03-10 | 一种构建人心肌细胞凋亡模型的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111411075A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112608972A (zh) * | 2020-12-21 | 2021-04-06 | 广东源心再生医学有限公司 | Myog基因作为靶点在制备治疗心肌细胞凋亡相关的心血管疾病的药物中的应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080070303A1 (en) * | 2005-11-21 | 2008-03-20 | West Michael D | Methods to accelerate the isolation of novel cell strains from pluripotent stem cells and cells obtained thereby |
US20090325288A1 (en) * | 2006-04-28 | 2009-12-31 | Asubio Pharma Co., Ltd. | Method for inducing differentiation of pluripotent stem cells into cardiomyocytes |
US20130029866A1 (en) * | 2011-07-21 | 2013-01-31 | Ning Sun | Cardiomyocytes from induced pluripotent stem cells from patients and methods of use thereof |
CN102994446A (zh) * | 2012-12-04 | 2013-03-27 | 罗国安 | 诱导胚胎干细胞定向分化为心肌细胞的诱导剂及培养基 |
CN110564677A (zh) * | 2019-08-09 | 2019-12-13 | 杭州标模生物科技有限公司 | 诱导多能干细胞分化为搏动心肌细胞的诱导剂及其应用 |
-
2020
- 2020-03-10 CN CN202010160710.6A patent/CN111411075A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080070303A1 (en) * | 2005-11-21 | 2008-03-20 | West Michael D | Methods to accelerate the isolation of novel cell strains from pluripotent stem cells and cells obtained thereby |
US20090325288A1 (en) * | 2006-04-28 | 2009-12-31 | Asubio Pharma Co., Ltd. | Method for inducing differentiation of pluripotent stem cells into cardiomyocytes |
US20130029866A1 (en) * | 2011-07-21 | 2013-01-31 | Ning Sun | Cardiomyocytes from induced pluripotent stem cells from patients and methods of use thereof |
CN102994446A (zh) * | 2012-12-04 | 2013-03-27 | 罗国安 | 诱导胚胎干细胞定向分化为心肌细胞的诱导剂及培养基 |
CN110564677A (zh) * | 2019-08-09 | 2019-12-13 | 杭州标模生物科技有限公司 | 诱导多能干细胞分化为搏动心肌细胞的诱导剂及其应用 |
Non-Patent Citations (3)
Title |
---|
GUIHUA ZHOU ET AL.: "Metallothionein suppresses angiotensin II-induced nicotinamide adenine dinucleotide phosphate oxidase activation, nitrosative stress, apoptosis, and pathological remodeling in the diabetic heart", 《J AM COLL CARDIOL》 * |
ZHENGBO ZHAO ET AL.: "Aliskiren attenuates cardiac dysfunction by modulation of the mTOR and apoptosis pathways", 《BRAZ J MED BIOL RES》 * |
王红贤 等主编: "《心律失常诊疗策略》", 31 July 2017, 科学技术文献出版社 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112608972A (zh) * | 2020-12-21 | 2021-04-06 | 广东源心再生医学有限公司 | Myog基因作为靶点在制备治疗心肌细胞凋亡相关的心血管疾病的药物中的应用 |
CN112608972B (zh) * | 2020-12-21 | 2021-09-10 | 广东源心再生医学有限公司 | Myog基因作为靶点在制备治疗心肌细胞凋亡相关的心血管疾病的药物中的应用 |
WO2022135279A1 (zh) * | 2020-12-21 | 2022-06-30 | 广东源心再生医学有限公司 | Myog基因作为靶点在制备治疗心肌细胞凋亡相关的心血管疾病的药物中的应用 |
US11919933B2 (en) | 2020-12-21 | 2024-03-05 | Guangdong Beating Origin Regenerative Medicine Co., Ltd. | Use of MYOG gene as target in preparation of drug for treating cardiomyocyte apoptosis-associated cardiovascular disease |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Dos Santos et al. | A xenogeneic‐free bioreactor system for the clinical‐scale expansion of human mesenchymal stem/stromal cells | |
Delgado et al. | Endothelial NT-3 delivered by vasculature and CSF promotes quiescence of subependymal neural stem cells through nitric oxide induction | |
US9080153B2 (en) | Treatment method for mesenchymal stem cells and their application as a treatment of oxidative stress related diseases | |
Weissman et al. | Paracrine modulation of androgen synthesis in rat leydig cells by nitric oxide | |
CN112608972B (zh) | Myog基因作为靶点在制备治疗心肌细胞凋亡相关的心血管疾病的药物中的应用 | |
CN110607277B (zh) | 一种人类多能干细胞分化巨噬细胞的方法 | |
CN111411075A (zh) | 一种构建人心肌细胞凋亡模型的方法 | |
Pinto et al. | Modulation of the in vitro angiogenic potential of human mesenchymal stromal cells from different tissue sources | |
Abbey et al. | Ascorbic acid-mediated enhanced cardiomyocyte differentiation of mouse ES-cells involves interplay of DNA methylation and multiple-signals | |
Zheng et al. | miRNA-185 regulates the VEGFA signaling pathway in dairy cows with retained fetal membranes | |
Szymanska et al. | The cAMP pathway promotes sirtuin-1 expression in human granulosa-lutein cells | |
Polisetti et al. | Gene expression profile of epithelial cells and mesenchymal cells derived from limbal explant culture | |
Gibbons et al. | Effects of oxygen tension on the establishment and lactate dehydrogenase activity of murine embryonic stem cells | |
Andreeva et al. | Controlled formaldehyde fixation of fibronectin layers for expansion of mesenchymal stem cells | |
CN111621470B (zh) | 一种高效低毒的心肌纯化培养基及方法 | |
Lee et al. | Vero cells, but not oviductal cells, increase the hatching frequency and total cell count of mouse blastocysts partly by changing energy substrate concentrations in culture medium. | |
Chabert et al. | Poly (ADPR) polymerase expression and activity during proliferation and differentiation of rat astrocyte and neuronal cultures | |
Heaney et al. | A technique for in vitro culture of canine valvular interstitial cells | |
Otegui et al. | RNA metabolism in isolated nuclei: processing and transport of immunoglobulin light chain sequences | |
Verma et al. | Signal regulatory protein alpha (SIRPA) and kinase domain receptor (KDR) are key expression markers in cardiac specific precursor selection from hADSCs | |
CN107177555A (zh) | 一种H9C2心肌细胞培养液诱导iPSCs定向心肌分化的方法 | |
Rallapalli et al. | Isolation, growth kinetics, and immunophenotypic characterization of adult human cardiac progenitor cells | |
CN107385020A (zh) | 瘦素在人重组fgf21蛋白活性检测中的应用 | |
WO2018156903A1 (en) | Methods for identifying and isolating cardiac stem cells and methods for making and using them | |
LEE et al. | Animal experimentation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200714 |